Sanjaya Singh
Overview
Explore the profile of Sanjaya Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
678
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Obermajer N, Zwolak A, van de Ven K, Versmissen S, Menard K, Rogers K, et al.
iScience
. 2025 Mar;
28(3):111876.
PMID: 40060890
T cell-redirecting bispecific antibodies (bsAbs) to treat advanced stage solid tumors are gaining interest after recent clinical successes. The immune checkpoint human leukocyte antigen G (HLA-G) is expressed in several...
2.
Jack Borrok M, Li Y, Harvilla P, Vellalore Maruthachalam B, Tamot N, Prokopowitz C, et al.
Cancer Res Commun
. 2023 Mar;
2(3):146-157.
PMID: 36874404
Significance: New approaches are needed to address relapsed/refractory disease and manage potential toxicities associated with CAR T-cell therapy. We describe an adapter CAR approach to redirect CAR T cells to...
3.
Edavettal S, Cejudo-Martin P, Dasgupta B, Yang D, Buschman M, Domingo D, et al.
Med
. 2022 Oct;
3(12):860-882.e15.
PMID: 36257298
Background: The near impermeability of the blood-brain barrier (BBB) and the unique neuroimmune environment of the CNS prevents the effective use of antibodies in neurological diseases. Delivery of biotherapeutics to...
4.
Wu H, Ralph K, Sepuldeva E, Hansen G, Li H, Huang Z, et al.
Int J Pharm
. 2021 Oct;
609:121162.
PMID: 34624444
Antibodies targeting the CD40-CD40L pathway have great potential for treating autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus (SLE), lupus nephritis (LN), and inflammatory bowel diseases (IBD). However, in addition...
5.
Ganesan R, Chennupati V, Ramachandran B, Hansen M, Singh S, Grewal I
Leukemia
. 2021 Feb;
35(8):2274-2284.
PMID: 33526858
Despite significant progress over the last few decades in the treatment of acute myeloid leukemia (AML), there still remains a major unmet medical need for this disease. Immunotherapy approaches for...
6.
Dees S, Ganesan R, Singh S, Grewal I
Eur J Immunol
. 2020 Dec;
51(2):280-291.
PMID: 33302322
The adaptive immune system is modulated by an important subset of CD4 T lymphocytes called Treg cells that function in maintaining immune homeostasis by preventing excessive immune activation. Both deficiency...
7.
Cortes-Selva D, Dasgupta B, Singh S, Grewal I
Trends Pharmacol Sci
. 2020 Nov;
42(1):45-59.
PMID: 33250273
Conventional αβ CAR-T cell-based approaches have revolutionized the field of cancer immunotherapy, but hurdles remain, especially for solid tumors. Novel strategies in conjunction with alternative cell types are therefore required...
8.
Dees S, Ganesan R, Singh S, Grewal I
Mol Cancer Ther
. 2020 Oct;
19(12):2409-2421.
PMID: 33087511
Triple-negative breast cancer (TNBC), a highly aggressive breast cancer subtype that lacks estrogen receptor, progesterone receptor, and HER2 expression, does not respond to traditional endocrine and anti-HER2-targeted therapies. Current treatment...
9.
Dees S, Ganesan R, Singh S, Grewal I
Trends Cancer
. 2020 Oct;
7(2):162-173.
PMID: 33041246
Triple negative breast cancer (TNBC), an aggressive breast cancer subtype lacking estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression, is associated with heightened metastatic...
10.
Gordon R, Nemeth J, Singh S, Lingham R, Grewal I
Trends Biotechnol
. 2020 Aug;
39(3):298-310.
PMID: 32807530
Intracellular delivery of therapeutic antibodies is highly desirable but remains a challenge for biomedical research and the pharmaceutical industry. Approximately two-thirds of disease-associated targets are found inside the cell. Difficulty...